- Home
- SEER vs ANL Comparison
SEER vs ANL Comparison
Compare SEER & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- ANL
- Stock Information
- Founded
- SEER 2017
- ANL 2004
- Country
- SEER United States
- ANL Cayman Islands
- Employees
- SEER N/A
- ANL 127
- Industry
- SEER Medicinal Chemicals and Botanical Products
- ANL
- Sector
- SEER Health Care
- ANL
- Exchange
- SEER Nasdaq
- ANL Nasdaq
- Market Cap
- SEER 114.3M
- ANL 115.1M
- IPO Year
- SEER 2020
- ANL 2023
- Fundamental
- Price
- SEER $2.31
- ANL $3.12
- Analyst Decision
- SEER Hold
- ANL Strong Buy
- Analyst Count
- SEER 1
- ANL 2
- Target Price
- SEER $3.00
- ANL $9.00
- AVG Volume (30 Days)
- SEER 276.5K
- ANL 29.1K
- Earning Date
- SEER 11-06-2024
- ANL 08-08-2024
- Dividend Yield
- SEER N/A
- ANL N/A
- EPS Growth
- SEER N/A
- ANL N/A
- EPS
- SEER N/A
- ANL N/A
- Revenue
- SEER $14,608,000.00
- ANL $5,000,000.00
- Revenue This Year
- SEER N/A
- ANL N/A
- Revenue Next Year
- SEER $40.36
- ANL N/A
- P/E Ratio
- SEER N/A
- ANL N/A
- Revenue Growth
- SEER N/A
- ANL N/A
- 52 Week Low
- SEER $1.47
- ANL $1.85
- 52 Week High
- SEER $2.50
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- SEER 63.86
- ANL 64.09
- Support Level
- SEER $2.15
- ANL $2.88
- Resistance Level
- SEER $2.50
- ANL $3.50
- Average True Range (ATR)
- SEER 0.13
- ANL 0.41
- MACD
- SEER 0.03
- ANL 0.12
- Stochastic Oscillator
- SEER 68.85
- ANL 60.19
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.